Everolimus plus exemestane for the treatment of advanced breast cancer: a review of subanalyses from BOLERO-2.
Everolimus plus exemestane for the treatment of advanced breast cancer: a review of subanalyses from BOLERO-2.
复制标题
DOI：
10.1016/j.neo.2015.01.005
复制
发表时间：
2015-03
期刊：
影响因子：
4.8
通讯作者：
Hortobagyi, Gabriel N.
中科院分区：
文献类型：
--
作者：
Hortobagyi, Gabriel N.
激素受体阳性乳腺癌通常用内分泌疗法治疗。然而，对内分泌治疗的抵抗导致大部分乳腺癌的疾病进展。通过对内分泌耐药机制的了解，对相关途径和靶点的鉴定导致了靶向这些途径的新型药物的开发。磷酸肌醇3-激酶/蛋白激酶B/哺乳动物雷帕霉素靶点（PI 3 K/AKT/mTOR）通路畸变在乳腺癌中很常见，PI 3 K/AKT/mTOR信号传导增加与内分泌和人表皮生长因子受体2（HER 2）靶向治疗的耐药性相关。根据乳腺癌口服依维莫司试验报告的结果，mTOR抑制剂依维莫司与依西美坦联合治疗已被批准用于既往非甾体芳香酶抑制剂治疗进展的晚期激素受体阳性/HER 2阴性乳腺癌患者。2（BOLERO-2）研究。本综述将总结来自BOLERO-2的总体结果，并将考虑按年龄、亚裔、内脏或骨转移和既往治疗进行的可用亚组分析，旨在确定最有可能从依维莫司治疗中获益的人群。该综述还将总结安全性结果及其管理以及依维莫司对生活质量的影响。
Hormone receptor–positive breast cancer is typically managed with endocrine therapies. However, resistance to endocrine therapy results in disease progression in a large proportion of breast cancers. Through the understanding of the mechanisms of endocrine resistance, identification of implicated pathways and targets has led to the development of novel agents targeting these pathways. Phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway aberrations are common in breast cancer, with increased PI3K/AKT/mTOR signaling associated with resistance to endocrine and human epidermal growth factor receptor 2 (HER2)–targeted therapies. The mTOR inhibitor everolimus, in combination with exemestane, has been approved for patients with advanced hormone receptor–positive/HER2-negative breast cancer who progress on prior nonsteroidal aromatase inhibitor therapy based on results reported in the Breast Cancer Trials of Oral Everolimus-2 (BOLERO-2) study. This review will summarize the overall findings from BOLERO-2 and will consider available subanalyses by age, Asian origin, visceral or bone metastases, and prior therapy, with the aim of identifying populations most likely to benefit from everolimus therapy. The review will also summarize safety findings and their management and the effects of everolimus on quality of life.
登录
查看更多内容
影响因子：
11.3
作者：
Ino, Yasushi;Kubo, Takashi;Akasaka, Takashi
通讯作者：
Akasaka, Takashi
影响因子：
3.1
作者：
Cleator, Susan J.;Ahamed, Eliyaz;Palmieri, Carlo
通讯作者：
Palmieri, Carlo
影响因子：
4.8
作者：
de Oliveira, Marcio Augusto;Martins e Martins, Fabiana;Treister, Nathaniel S.
通讯作者：
Treister, Nathaniel S.
影响因子：
3.6
作者：
Bachman, KE;Argani, P;Park, BH
通讯作者：
Park, BH
影响因子：
3.8
作者：
Beck, J. Thaddeus;Hortobagyi, Gabriel N.;Campone, Mario;Lebrun, Fabienne;Deleu, Ines;Rugo, Hope S.;Pistilli, Barbara;Masuda, Norikazu;Hart, Lowell;Melichar, Bohuslav;Dakhil, Shaker;Geberth, Matthias;Nunzi, Martina;Heng, Daniel Y. C.;Brechenmacher, Thomas;El-Hashimy, Mona;Douma, Shyanne;Ringeisen, Francois;Piccart, Martine
通讯作者：
Piccart, Martine